BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
Seeking Alpha on MSN1h
BioNTech to buy bispecific antibody developer Biotheus for up to $950MThe deal, which is expected to close in Q1 2025, will give BioNTech (BNTX) full global rights to BNT327/PM8002, a PD-L1 x VEGF-A bispecific antibody that the companies believe has the potential to ...
co-founder and chief medical officer of BioNTech. "We must not forget that cancer is also a global health threat, even worse than the current pandemic," she added. Discover how AI is ...
BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines.
Time on MSN15d
Why You Might Need Two COVID-19 Shots This SeasonS eniors and people who are immunocompromised should get not just one but two COVID-19 shots this respiratory virus season.
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering ... regarding its COVID-19 vaccine with governmental authorities, private health ...
The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of ... through a global license from OncoC4, and the firms hope that ...
November 13th has seen a myriad of significant events throughout history, impacting various spheres such as politics, science ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback